

Date 18/06/2026  
Your Ref  
Our Ref 11519

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to prescribing.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Avelumab (Bavencio) = 8
- Atezolizumab (Tecentriq) = 16
- Pembrolizumab (Keytruda) = 169
- Nivolumab (Opdivo) = 34
- Durvalumab (Imfinzi) = 14
- Erdafitinib (Balversa) = 0
- Enfortumab vedotin (Padcev) = 0
- Cisplatin = 30
- Carboplatin = 20
- Gemcitabine = 11

Question:

2. How many patients were treated with avelumab (Bavencio) for the following types of cancer in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Merkel Cell Carcinoma (ICD-10 codes = C4A\* and/or morphology code = 8247/3) = 0
- Urothelial Carcinoma (ICD-10 codes = C65\*, C66\*, C67\* and/or morphology code = 8120\*, 8130\*, 8131/3, 8122/3, 8031/3) = 8
- Renal Cell Carcinoma (C64\*) = 0
- Other types of tumour = 0

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common  
name of Lothian Health Board*

Question:

3. How many patients with **Renal Cell Carcinoma (RCC)** were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Avelumab + Axitinib = 0

Question:

4. How many patients with Urothelial Carcinoma (UC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Avelumab Monotherapy Maintenance = 8
- Atezolizumab = 0
- Pembrolizumab Monotherapy = 7
- Pembrolizumab + Enfortumab vedotin = 0
- Nivolumab Monotherapy = 5 or fewer
- Nivolumab + Cisplatin + Gemcitabine = 0
- Durvalumab Monotherapy Maintenance = 0
- Durvalumab + Gemcitabine + Cisplatin = 0
- Carboplatin+ Gemcitabine = 6
- Paclitaxel Monotherapy = 0
- Carboplatin + Paclitaxel = 0
- Cisplatin + Gemcitabine = 5 or fewer

Question:

5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Aflibercept – (Zaltrap only) = 0
- Bevacizumab = 25
- Cetuximab = 5 or fewer
- Encorafenib = 0
- Fruquintinib = 0
- Nivolumab = 34
- Panitumumab = 5 or fewer
- Pembrolizumab = 169
- Regorafenib = 5 or fewer
- Trifluridine + Tipiracil (Lonsurf) = 0

Question:

6. How many patients were treated for Colorectal Cancer (ICD-10 codes C18\*, C19\*, C20\*, D010, D011, D012) with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Bevacizumab = 15
- Cetuximab = 5 or fewer
- Encorafenib = 0
- Nivolumab = 0
- Pembrolizumab = 10
- Regorafenib = 5 or fewer
- Trifluridine + Tipiracil (Lonsurf) = 0

Question:

7. How many patients were treated for Colorectal Cancer (ICD-10 codes C18\*, C19\*, C20\*, D010, D011, D012) with the following combinations or chemotherapy and other agents in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Bevacizumab + Trifluridine + Tipiracil = 8
- Bevacizumab + FOLFOX = 0
- Bevacizumab + FOLFIRI = 0
- Cetuximab + FOLFIRI = 10
- Cetuximab + FOLFOX = 5 or fewer
- Cetuximab + FOLFIRINOX / FOLFOXIRI = 0
- Cetuximab Monotherapy = 5 or fewer
- Panitumumab + FOLFIRI = 5 or fewer
- Panitumumab + FOLFOX = 5 or fewer
- Panitumumab + FOLFIRINOX / FOLFOXIRI = 0
- Capecitabine + Oxaliplatin (XELOX) = 0
- Capecitabine + Irinotecan (XELIRI) = 5 or fewer

To protect the identity of the individuals involved any figure of 5 or less has not been shown in this response. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.



If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive